CiteFacts · FDA Drug Shortages · FDA source
FDA shortage status: Sufentanil Citrate Injection
FDA source answer
FDA currently lists this ingredient in shortage.
FDA source statuses: Current. First FDA posting: 2022-05-03. Latest FDA row update: 2026-09-22.
FDA lists 4 package records, with companies: Hikma Pharmaceuticals USA, Inc., Hospira, Inc., Hospira, Inc., a Pfizer Company. Package NDCs: 0409-3382-21, 17478-050-01, 17478-050-02, 17478-050-05.
FDA shortage reason: Other
This is nationwide FDA status, not local pharmacy inventory. CiteFacts does not provide medical, treatment, substitution, or dosing advice.
FDA package and manufacturer records
| Company | Package NDC | Presentation | FDA availability field | FDA update |
|---|---|---|---|---|
| Hikma Pharmaceuticals USA, Inc. | 17478-050-01 | Sufentanil Citrate, Injection, 50 mcg/1 mL (NDC 17478-050-01) | Unavailable | 2026-09-18 |
| Hikma Pharmaceuticals USA, Inc. | 17478-050-02 | Sufentanil Citrate, Injection, 50 mcg/1 mL (NDC 17478-050-02) | Unavailable | 2026-09-18 |
| Hikma Pharmaceuticals USA, Inc. | 17478-050-05 | Sufentanil Citrate, Injection, 50 mcg/1 mL (NDC 17478-050-05) | Unavailable | 2026-09-18 |
| Hospira, Inc., a Pfizer Company | 0409-3382-21 | Sufentanil Citrate, Injection, 50 ug/1 mL (NDC 0409-3382-21) | Available | 2026-09-22 |
Source facts
Grouped generic ingredient: Sufentanil Citrate Injection · 4 package records
Therapeutic categories: Analgesia/Addiction, Pediatric
Dosage forms: Injection
Routes: EPIDURAL, INTRAVENOUS
Open FDA source data · JSON · Markdown
FDA is authoritative. Source retrieved 2026-10-06T18:55:41+00:00. Derived grouping is documented in this record's derivations.